MedTech Dive September 8, 2025
BTIG analysts said Senseonics is doubling down on its belief an inflection point in patient demand is imminent, but the company will need a large sales force to win market share.
Dive Brief:
- Senseonics has struck a deal to retake control of the commercialization and distribution of its implantable continuous glucose monitors, the company said Wednesday.
- Ascensia Diabetes Care is currently the exclusive worldwide distributor of the Eversense devices. That will change at the start of 2026, when Senseonics will resume responsibility.
- BTIG analysts said in a note to investors that the move shows “Senseonics is doubling down on its view that the one-year sensor will finally enable an inflection in patient demand for the implantable glucose monitor.”
Today's Sponsors
Today's Sponsor